← Eichor
Study identifier: NCT05517291 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

DCB Versus Primary Selective Stenting in TASC C/D Femoropopliteal Artery Disease

Condition: Safety Issues · Efficacy, Self  ·  Sponsor: Peking Union Medical College Hospital

PhaseNA
Planned participants200
Who can joinAll sexes, 18 Years to 85 Years
Healthy volunteersNo

About this study

This study aims to compare the mid- and long-term outcomes between paclitaxel-coated balloon and primary selective stenting in the treatment of TASC C/D femoropopliteal artery occlusive disease.

This description comes directly from the study's public registry record.

Talk to the study team

Leng Ni, MD  ·  86-1069152501  ·  nileng@163.com

Always discuss trial participation with your own doctor first.

Locations (1)

Peking Union Medical College HospitalBeijing, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05517291